SCHEDULE 13G/A: BlackRock Amends Schedule 13G, Disclosing 6.9% Stake in Charles River Laboratories

BlackRock, Inc. has filed an amended Schedule 13G, reporting a 6.9% beneficial ownership stake in Charles River Laboratories International Inc. as of March 31, 2025.

Summary

• BlackRock, Inc. reported beneficial ownership of 3,524,401 shares of Common Stock in Charles River Laboratories International Inc.
• This ownership represents 6.9% of the total outstanding common shares of Charles River Laboratories International Inc.
• BlackRock, Inc. holds sole voting power over 3,347,541 shares and sole dispositive power over 3,524,401 shares.
• The filing certifies that the securities were acquired and are held in the ordinary course of business and not for the purpose of changing or influencing the control of the issuer.
• BlackRock Fund Managers Ltd is specifically identified as an entity within BlackRock, Inc. that beneficially owns 5% or greater of the outstanding shares.

Sentiment

Score: 5

Explanation: The document is a routine regulatory filing disclosing beneficial ownership, providing factual information without indicating positive or negative performance or outlook for the issuer.

Future Outlook

This document does not provide any forward-looking statements or guidance regarding Charles River Laboratories International Inc.'s future performance or outlook.

Management Comments

• "By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under §§ 240.14a-11." (Signed by Spencer Fleming, Managing Director of BlackRock, Inc.)

Industry Context

This filing is a routine disclosure by a major institutional asset manager, BlackRock, Inc., regarding its passive investment stake in Charles River Laboratories, a company operating in the life sciences industry. It reflects BlackRock's portfolio management activities rather than specific industry trends or competitive dynamics for Charles River Laboratories.

Stakeholder Impact

• Shareholders: Provides transparency regarding the significant ownership stake held by a major institutional investor, BlackRock, Inc.
• Company (Charles River Laboratories): Awareness of a substantial passive investment by a large asset manager.

Next Steps

• BlackRock, Inc. will continue to monitor its investment in Charles River Laboratories International Inc. and will file further amendments to Schedule 13G if its beneficial ownership percentage changes significantly (e.g., by 1% or more).

Key Dates

Keywords

BlackRock, Charles River Laboratories, CRL, Schedule 13G, Beneficial Ownership, Institutional Investor, Common Stock, SEC Filing